Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy and cellular building blocks. These metabolic alterations are mediated by many oncogenic changes that affect cellular signalling pathways, which result in sustained cell growth and proliferation. Recently, metabolomics has received great attention in the field of cancer research, and as the essential metabolic pathways that drive tumour growth and progression are determined the possibilities of new targets for therapeutic intervention are opened. More specifically, as breast cancer is a heterogeneous disease, there is growing evidence that differences in metabolic changes exist between molecular subtypes. In this review, the most recent findings in breast cancer cell metabolism are discussed, with particular emphasis on glutamine and its transporters, which is considered one of the key amino acids fuelling cancer growth. Furthermore, the metabolic differences between the molecular subtypes of breast cancer are examined, highlighting the clinical utility for breast cancer diagnosis and treatment.
Introduction
One of the hallmarks of cancer, 1 altered metabolic profile, has been demonstrated for many years, and the significance of cancer metabolism and its exploitation for anticancer therapy has recently attracted great attention. The relentless proliferation of cancer cells is metabolically demanding, requiring adenosine triphosphate (ATP) generation for the necessary energy and production of metabolic intermediates. The latter are the precursors for cellular 'building blocks' in the form of nucleotides for DNA/RNA, amino acids for proteins and fatty acids for lipids. In addition to increasing the amount of metabolites the cells require, cancer cells actively alter the way nutrients are used. This adaptation process has been termed 'metabolic transformation'. 2 In order to fuel the aberrant proliferation, cancer cells reprogramme their glucose metabolism. Glycolysis is elevated normally under anaerobic conditions and is the major source of energy in malignant tumours, even with the presence of oxygen -a phenomenon known as aerobic glycolysis or the Warburg effect, 3, 4 where glucose is converted mainly to lactate rather than engaging in the mitochondrial oxidative phosphorylation. Glutamine is the second primary metabolite to nourish cancer cell proliferation. Although it is a non-essential amino acid in normal cells, glutamine becomes essential to the proliferative neoplastic cells and certain cancer cell types become 'addicted' to glutamine as they fail to grow or proliferate in its absence. 5 Glutamine metabolism not only assists ATP production, it is also essential for biosynthesis of nucleotides, lipid and proteins, in addition to its role as a regulator for redox balance. 6 SLC1A5 (ASCT2) and SLC7A5 (LAT1) are the key cellular glutamine transporters which show higher affinity for their substrates and both are up-regulated in a variety of cancers where their expression pattern is comparable. 7 Changes in glutamine metabolism are controlled by activated oncogenes (e.g. MYC) and/or loss of tumour suppressors, e.g. retinoblastoma (Rb), which can enhance the uptake and utilisation via up-regulation of cellular transporters and enzymes supporting tumour replication and giving rise to aggressive cancer phenotypes. 8, 9 Breast cancer (BC) is a heterogeneous disease characterised by different morphology, clinical outcome and response to treatment. Based on the gene expression profile, BC can be classified into different molecular subtypes; luminal A (ER and/or PR -positive, HER2-negative, low Ki67), luminal B (ER and/or PRpositive, HER2-positive or HER2-negative with high Ki67), basal-like tumours (mainly triple-negative BC) and HER2-positive (ER/PR-negative, HER2-positive). Luminal tumours usually confer good clinical outcome, while the last two subtypes confer shorter relapse-free and overall survival.
10,11 BC also shows heterogeneity in the metabolic reprogramming, including glutamine metabolism. Therefore, understanding the cellular metabolism in different subtypes will help in identifying potential novel therapeutic targets.
This review highlights the metabolic modulations in breast cancer, with emphasis on the role of altered glutamine metabolism and glutamine transporters in the different molecular subtypes.
Glutamine metabolism in breast cancer cells
Non-essential amino acids are synthesized endogenously by mammalian cells. However, in tumour cells they become essential in order to meet the needs of rapid cell growth. 12 Glutamine is the second most essential nutrient used after glucose for driving tumour cell proliferation and survival, 13 with some cancer cells displaying glutamine addiction, to facilitate cell metabolism and sustain growth. Glutamine can provide the tumour cell with several mechanisms to achieve this ( Figure 1 ). First, glutamine provides the nitrogen required for the biosynthesis of nucleotides and non-essential amino acids.
14 In addition, glutamine can replenish the mitochondrial tricarboxylic acid cycle (TCA) carbon pool via a-ketoglutarate (a-KG) synthesis and, subsequently, a-KG can undergo reductive carboxylation which supports citrate and fatty acid synthesis in stress conditions such as hypoxia. 15, 16 Alternatively, glutamine can be metabolised by glutaminases to provide glutamate. The latter is a precursor for glutathione (GSH), which is used to reinforce the antioxidant response and maintain the redox balance within cancer cells. 17, 18 A further role for glutamine is facilitating the import of essential amino acids, including leucine, which maintains activation of the mammalian target of rapamycin complex 1 (mTORC1) which, in turn, regulates protein translation and prevents apoptosis in cancer cells. 19 Furthermore, in tumours that bear mutations in isocitrate dehydrogenase (IDH1/IDH2), such as glioma 20 and cholangiocarcinoma, 21 mitochondrial glutamine may be a source for 2 hydroxyglutarate (2HG), which competitively inhibits a-KG-dependent dioxygenase. If accumulated, 2HG causes aberrations in DNA and histone methylation that result in increased stem cell marker expression indicating a switch to a stem-like phenotype in cancer cells. 22, 23 It has been found that 2HG can be accumulated in MYC-driven BC without IDH mutation. 24 Both triple-negative BC (TNBC) and HER2-positive breast cancers have higher levels of glutamine consumption and glutaminolysis compared with luminal subtypes. 25 
Mutational landscapes control glutamine and glucose metabolism in breast cancer
Glucose and glutamine serve as the primary nutrients to fuel cancer cell proliferation and, indeed, the rate of their utilisation far exceeds the consumption of other nutrients. It has been found that the metabolism of these two nutrients is co-regulated, as cancer cells which depend upon glycolysis must increase the rate of glutamine consumption to provide a-KG to the TCA cycle for further production of intermediates required for biosynthetic pathways. This reprogramming is controlled by mutations in oncogenes and/or tumour suppressors, or more directly by copy number aberrations of metabolic genes themselves. 26 The most frequent of these aberrations is TP53 mutations, which occur in approximately 80% of basal-like and HER2-positive tumours. 27 Wild-type P53 targets cytochrome C oxidase-2 (SCO2), which promotes aerobic respiration, and TP53-induced glycolysis regulatory phosphatase (TIGAR), which inhibits glycolysis. Thus, loss of TP53 function shifts metabolism towards aerobic glycolysis and Warburg metabolism. 28, 29 In addition, mutations in PI3K pathway, which occur commonly in the luminal subtypes of BC, not only stimulate glycolysis through the growth factor (PI3K/Akt/mTOR) signalling pathway, 30 it also induces glycolysis through the activation and mobilisation of aldolase A from the actin cytoskeleton. 31 The oncogene MYC is amplified in approximately 15% of breast cancers, particularly in basal-like tumours, with a lower occurrence in HER2-positive and luminal subtypes. 32 MYC is known to divert glucose metabolism towards aerobic glycolysis and lactate production. Simultaneously, it has a robust influence in glutamine metabolism as it facilitates glutamine uptake directly by binding to the promotors and inducing the expression of glutamine transporters (e.g. SLC1A5 and SLC38A5). It also promotes indirectly the expression of glutaminase (GLS1) by repressing the expression of miR 23 a/b, miRNAs that repress the expression of this enzyme. 33, 34 Additionally, MYCdriven ER-negative tumours showed GLS overexpression and 2HG accumulation, conferring poor overall survival. 24 Glutamine uptake can also be regulated by Rb family proteins via controlling the E2F-3 transcription factor, which associates with the SLC1A5 promoter and regulates its gene expression directly where Rb knockout cells exhibit elevated SLC1A5 when compared to Rb wild-type cells. Role of glutamine in supporting tumour growth. GLUT, glucose transporter; TCA, tricarboxylic acid cycle; AC-coA, acetyl coenzyme A; OAA, oxaloacetate; a-KG, a-ketoglutarate; LDH, lactate dehydrogenase; GLS, glutaminase; GLUD, glutamate dehydrogenase; 2HG, 2 hydroxyglutarate. Glucose and glutamine are the two essential metabolites used to fuel cancer cells. Glutamine plays an essential role in supporting cancer cell growth. Glutamine can act as a nitrogen donor and assist nucleotide biosynthesis and the synthesis of other essential amino acids. Additionally, Glutamine can be metabolized by glutaminases to provide glutamate. The latter, is a precursor for glutathione, which neutralizes the reactive oxygen species (ROS). Furthermore, glutamate can be converted to a-KG, which is used to replenish the TCA cycle. a-KG can also be a precursor for the oncometabolite (2HG), which causes methylation-specific changes and increases the expression of stem cell markers. Glucose and glutamine are the two essential metabolites used to fuel cancer cells. Glutamine is imported into the cells through glutamine transporters (e.g. SLC1A5) and its efflux is coupled by influx of leucine, through SLC7A5, the amino acid which activates mTORC1 and subsequently supports cancer cell proliferation. [38] [39] [40] Similarly, it has been reported that the highly invasive MDA-MB-231 (TNBC) cell line has much higher glucose consumption rates than MCF7 cells (ER-positive, luminal A). 41 Glutamine-dependent mechanisms also can vary substantially among breast cancer subtypes. TNBCs have increased expression of glutamine metabolic enzymes. 42 However, the highest levels of glutamine metabolism with increased GLS and glutamate dehydrogenase (GLUD) expression are observed in HER2-positive breast cancer, while luminal A tumours have the lowest level of these enzymes. 25 This is in concordance with higher levels of glutamate and lower levels of glutamine in TNBC and HER2-positive tumours compared with ER-positive tumours, suggesting an increase in glutamine consumption and glutaminolysis in these tumours. 38, 39 Subsequently, glutamine deprivation can reduce the proliferation and progression especially among the most aggressive types of breast cancer.
Metabolic signature in breast cancer varies among different molecular classes
Recently, metabolic profiling of breast tumours has demonstrated a large difference between malignant and normal breast cells, 36,37 which has been established further within the different molecular breast cancer subtypes, where ER-negative tumours can be distinguished from those that are ER-positive depending on their metabolic signatures. Breast cancer cells have been shown to overexpress glucose transporters and glycolytic enzymes involved in the metabolic process. For example, Kanaan et al. reported an elevated level of almost all glycolytic intermediates with strong lactate accumulation in TNBC when compared to ER-positive tumours. However, there was a slight decrease in citrate observed in TNBC, indicating an increase in Warburg metabolism, where glucose-derived pyruvate is shunted to lactate, and citrate is utilised in fatty acid biosynthesis.
Glutamine transporters and their relevance to breast cancer
In general, all amino acids, including glutamine, require the aid of selective transporters to be able to cross the plasma membrane. Approximately 14 amino acid transporters accept glutamine as a substrate. However, none are solely selective for this amino acid, as they also transport other neutral, cationic and anionic amino acids. Furthermore, they function either in the influx or efflux of glutamine into/from cells. These transporters belong to four different gene families: solute carrier family (SLC) SLC1, SLC6, SLC7 and SLC38; namely, SLC1A5, SLC6A14, SLC6A19, SLC7A5-9 and SLC38A1-3, -5 and 7-8.
22 Table 1 summarises the glutamine transporters along with their functions and relevance to breast cancer.
Reviewing all the glutamine transporters is beyond the scope of this review; however, within the field of breast cancer metabolism, SLC1A5 and SLC7A5 have been attracting particular attention due to their role in supporting tumour metabolism and potential as a therapeutic target within the aggressive subclasses of BC.
SLC1A5 and SLC7A5 are both expressed in the aggressive subtypes of breast cancer, indicating that the two transporters cooperate at the functional level in promoting tumour growth, as SLC1A5 maintains the sodium-coupled influx of glutamine, which preserves the biosynthetic pathway of the rapidly growing cancer cells, whereas SLC7A5 mediates the efflux of this amino acid in exchange with the influx of leucine, an essential amino acid and potent activator of mTORC1 ( Figure 1) .
It is known that c-MYC enhances the expression of SLC1A5 and SLC7A5 through binding to their promotor regions. 39, 40 Upon glutamine deprivation, activation factor 4 (ATF4), in coordination with MYC, activates the expression of both transporters directly to maintain intracellular levels of amino acids. 41, 42 High expression of SLC1A5 and SLC7A5 was observed in TN-and HER2-positive BC compared with luminal subtypes. 20, 43 Recent work carried out by our group (data unpublished) has shown that SLC1A5 and SLC7A5 proteins are expressed predominantly in the membrane of the more aggressive ER-positive luminal B tumours, where it confers a poor patient outcome (Figure 2A,B) . In addition, cases which exhibited coexpression of both transporters showed a poorer outcome compared to the single expression of each protein. Indeed, SLC7A5 is included, along with other immunohistochemical markers, in the Mammostrat â test, which predicts the recurrence rate of early stage breast cancer patients treated with endocrine therapy. 43 In addition, it is shown that this biomarker, along with carcinoembryonic antigen-related adhesion molecules (CEACAM5 and CEACAM6), can act as a predictor of poor response to neoadjuvant chemotherapy in locally advanced breast cancer. Therefore, it will be possible to limit the toxicity of chemotherapy of non-responder patients. 44 Other glutamine transporters that have been investigated in breast cancer include SLC6A14 and SLC7A8, which are up-regulated in ER-positive but not ER-negative breast tumours. 45, 46 In addition, SLC7A7 may be considered a progesterone receptor (PR) target gene, as a study carried out by Leo et al. showed a 6.5-fold expression change within the TNBC cell line MDA-MB-231 after PR-transfection. 47 Additionally, SLC7A7, along with SLC7A8, SLC7A9 and SLC38A5, are overexpressed in HER2-positive breast cancer cell lines. 48 Moreover, SLC38A1 is up-regulated and overexpressed in different breast cancer cell lines, particularly those that are ER-negative, compared with normal breast tissues. 49 SLC38A2 has not been investigated in specific breast cancer subtypes, but it has been found to be upregulated by BRCA1 which is associated frequently with basal-like TNBC. 50, 51 Other glutamine transporters have yet to be studied in breast cancer.
Metabolic biomarkers can be exploited to predict breast cancer progression and response to therapy Various metabolic pathways of cancer cells harbour targets that can be exploited for treatment of malignant diseases, including breast cancer. These agents can deactivate the essential pathways, which result in lack of energy and the necessary molecules required for cancer cell growth and survival.
Breast cancer patients with ER-and HER2-positive subtypes respond well to endocrine therapies and anti-HER2 agents, respectively. However, some cancers exhibit resistance. Moreover, conventional chemotherapy remains the main strategy for treating the aggressive TNBC, as targeted therapy is currently lacking for these tumours. Therefore, cellular metabolism in breast cancer may be promising for developing targeted therapies with fewer complications, and which may also reverse drug resistance. Metabolic approaches, including liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR) spectroscopy, can be applied to analyse different metabolites in tumour tissue and plasma in order to identify novel diagnostic and prognostic • Have yet to be studied in breast cancer biomarkers, as well as providing a new anticancer agents, especially in tumours that lack response to conventional treatment. Differences in metabolic signatures between ERnegative and ER-positive breast tumours may further guide therapy and predict disease outcome. GLS inhibitor CB-839, for example, is being assessed currently in Phase II clinical trials in many solid tumours, including in patients with TNBC. 52 Similarly, targeting glutamine transporters in vitro show a considerable inhibitory effect on these highly aggressive breast cancer cells. 42, 53 Interestingly, TNBC cells are particularly sensitive to the pharmacological inhibition of mTORC1. 54 Similarly, a clinical trial showed that trastuzumab-refractory HER2-positive patients can be treated actively with mTORC1 inhibitors combined with anti-HER2 agents.. 55 Accordingly, targeting SLC1A5 and SLC7A5 may afford a potential role in treating patients with the most aggressive breast cancer subtypes through impeding the import of leucine and subsequent mTORC1 activation. Thus, designing specific inhibitors which target this pathway should be investigated further.
Targeting the transcription factor MYC is another aspect that can be exploited for blocking cancer metabolism, especially for glutamine import and catabolism. It has been challenging to target the pleotrophic MYC therapeutically. However, the small molecule inhibitor CX-3543, that binds G-quadruplexes which exist in the MYC promoter, is currently being tested in Phase II clinical trials. 56, 57 Targeting metabolic reprogramming can be potentially useful as a strategy to overcome resistance to therapy. It has been found that enhanced Warburg metabolism, via AKT/mTOR/HIF-1a modulations, is one of the mechanisms for deriving tamoxifen resistance, and impairing glycolysis can restore tamoxifen sensitivity in endocrine-resistant BC cells. 58 Similarly, Zhao et al. found that increased glycolysis in HER2+ cancer cells, through the up-regulation of heat shock factor 1 (HSF1) and lactate dehydrogenase A (LDHA), can participate in trastuzumab resistance, as a combination of glycolysis inhibitor and the anti-HER2+ drug inhibited the growth of trastuzumab-resistant breast cancer.
It is important to note that cancer cells exhibit metabolic plasticity which allows them to survive and grow under unfavourable and stressful environments, making this character a major issue facing metabolic targeting of cancer cells. Targeting a particular metabolic pathway may not be sufficient as a viable strategy for cancer treatment, as tumour cells could develop resistance through expressing other alternative pathways. For example, metastatic breast cancer shows striking plasticity to adapt their metabolism and growth under different conditions.
To allow exposure to microenvironmental changes which give a better representation of in-vivo systems, magnetic resonance spectroscopy (MRS) was applied by Simões et al. in a high-density three-dimensional in-vitro model. They observed that under glutamine starvation, metastatic breast cancer cells (4T1) showed increased pyruvate carboxylase activity, which catalyses the carboxylation of pyruvate to form oxaloacetate (OAA), while glutamine supply can cause a decrease in the activity of this enzyme, as more glutamine is available to replenish the TCA cycle at the level of OAA. This indicates the presence of an alternative pathway into the TCA cycle driven by glutamine and independent of glucose. 59 Therefore, to obtain a more effective anticancer therapy of metastatic breast cancer both pathways, glycolysis and oxidative phosphorylation should be targeted. In addition, it can be suggested that the synergistic lethality targeting both glutamine and glucose pathways may prove to be more effective in the treatment of cancer, taking into account the toxic effect of these on normal cells, otherwise this treatment regimen may be accompanied by the same types of toxicity caused by conventional chemotherapy.
Conclusion
Breast cancers exhibit disparity among their molecular classes for the relative importance of metabolic pathways. The most prominent is the aggressive metabolic pattern of TNBC and changes in the glutamine pathway. Studying the metabolic pathways of these breast cancer subtypes can lead to the discovery of candidate biomarkers, as well as providing novel agents which can guide to a personalised treatment. Designing metabolic targeting agents with synergistic lethality may prove to be more effective in cancer treatment. Overall, the integration of metabolomic characteristics of breast cancer with genomic, transcriptomic and proteomic data is a way forward towards a more comprehensive understanding of the disease progression and response to therapy.
